France : Press Release: Dupixent (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old

Press/Media

Period14 Oct 2022 → 17 Oct 2022

Media coverage

3

Media coverage